Elizabeth Holmes Verdict Breakdown in Theranos Fraud Case
(Bloomberg) -- Elizabeth Holmes was found guilty on four of 11 criminal charges against her. She was found not guilty of four charges, and jurors were unable to reach a verdict on three.
Here's the breakdown of each count:
- GUILTY on Count No. 1 (conspiracy) -- Holmes conspired with former Theranos Inc. President Ramesh “Sunny” Balwani to defraud investors from 2010 to 2015.
- NOT GUILTY on Count No. 2 (conspiracy) -- Charge of conspiring with Balwani to defraud Theranos patients from 2013 to 2016.
- NO VERDICT on Count No. 3 (wire fraud) -- A former money manager and financial planner from Houston claimed that after investing about $1 million in the company when it was young, he tried in vain for years to get straight answers about the blood-testing startup from Holmes and Balwani.
- NO VERDICT on Count No. 4 (wire fraud) -- Chris Lucas, a venture capitalist whose uncle, Donald Lucas, was an early Theranos investor and had served on the startup's board, claimed he poured about $5 million in the company knowing it was a risk, but confident that it had good prospects with Holmes at the helm.
- NO VERDICT on Count No. 5 (wire fraud) -- An executive of a Dallas-based real estate investment firm who had overseen an early $2 million investment in Theranos claimed he approved investing an additional $5 million after listening to Holmes on a 2013 conference call with investors -- a recording of which was played for the jury.
- GUILTY on Count No. 6 (wire fraud) -- Brian Grossman, a hedge fund manager at PFM Health Sciences, claimed he did extensive research on Theranos before buying $96 million of private shares in the startup on behalf of institutional investors, pension funds and a “friends and family fund” for less wealthy individuals.
- GUILTY on Count No. 7 (wire fraud) -- An investment adviser for the Betsy DeVos and her relatives claimed Holmes courted the family with voluminous investment binders, private conversations, a lengthy tour of the company, and a personalized on-site blood test.
- GUILTY on Count No. 8 (wire fraud) -- An estate lawyer for Henry Kissinger said he helped Theranos line up investments totaling $370 million from from some of the wealthiest families in the U.S. -- the Waltons, the Coxes, the Oppenheimers and the DeVoses.
- NOT GUILTY on Count No. 10 (wire fraud) -- A patient claimed she got a false positive HIV antibody result on a Theranos blood test.
- NOT GUILTY on Count No. 11 (wire fraud) -- A patient claimed a faulty Theranos test result led him to believe he had an aggressive form of prostate cancer.
- NOT GUILTY on Count 12 (wire fraud) -- Theranos spent $1.1 million on advertising to encourage consumers to patronize company-branded wellness centers.
NOTE: Count No. 9 was withdrawn by prosecutors during the trial.
©2022 Bloomberg L.P.
-
India's Troika Of Good Luck | Joining The Dots
A weaker Trump, a cooling AI trade and resilient earnings have put Indian markets back in favour. Rising inflation could spoil the party.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.